OVERVIEW OF ACTIVITY
Lung cancer is a devastating disease with broad-reaching impact on public health as it accounts for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In 2013, it is estimated that 228,190 new cases will be diagnosed and 159,480 deaths will occur from the disease. In addition, only 16% of all patients with lung cancer are alive 5 years or more after diagnosis, despite currently available therapies.

OVERVIEW OF ACTIVITY

Results from 2 Phase III studies with maintenance pemetrexed and/or bevacizumab in patients with advanced nonsquamous NSCLC

Zinner R et al. Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). Proc ASCO 2013;Abstract LBA8003.

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists and other healthcare providers involved in the treatment of breast cancer.